Literature DB >> 26626636

Hepatitis C virus strategies to evade the specific-T cell response: a possible mission favoring its persistence.

Jorge Fabián Quarleri1, José Raúl Oubiña2.   

Abstract

Hepatitis C virus (HCV) is a small, enveloped RNA virus. The number of HCV-infected individuals worldwide is estimated to be approximately 200 million. The vast majority of HCV infections persist, with up to 80% of all cases leading to chronic hepatitis associated with liver fibrosis, cirrhosis, and hepatocellular carcinoma. The interaction between HCV and the host have a pivotal role in viral fitness, persistence, pathogenicity, and disease progression. The control of HCV infection requires both effective innate and adaptive immune responses. The HCV clearance during acute infection is associated with an early induction of the innate and a delayed initiation of the adaptive immune responses. However, in the vast majority of acute HCV infections, these responses are overcome and the virus persistence almost inexorably occurs. Recently, several host- and virus-related mechanisms responsible for the failure of both the innate and the adaptive immune responses have been recognized. Among the latter, the wide range of escape mutations to evade the specific-T-and B-cell responses as well as the T cell anergy and the CD8+ T cell exhaustion together with the interference with its function after prolonged virus exposure hold a pivotal role. Other HCV strategies include the modification or manipulation of molecules playing key roles in the induction of the interferon response and its induced effector proteins. In this review, we attempt to gain insights on the main T cell immune evasion strategies used by the virus in order to favor its persistence.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26626636     DOI: 10.5604/16652681.1184193

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  4 in total

1.  Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.

Authors:  Timothy T Spear; Timothy P Riley; Gretchen E Lyons; Glenda G Callender; Jeffrey J Roszkowski; Yuan Wang; Patricia E Simms; Gina M Scurti; Kendra C Foley; David C Murray; Lance M Hellman; Rachel H McMahan; Makio Iwashima; Elizabeth Garrett-Mayer; Hugo R Rosen; Brian M Baker; Michael I Nishimura
Journal:  J Leukoc Biol       Date:  2016-02-26       Impact factor: 4.962

2.  Inflammation response and liver stiffness: predictive model of regression of hepatic stiffness after sustained virological response in cirrhotics patients with chronic hepatitis C.

Authors:  Aline Márcia Marques Braz; Fernanda Cristina Winckler; Larissa Sarri Binelli; Luis Guilherme Chimeno; Lia Beatriz Mantovani Lopes; Rodrigo Santos Lima; Rafael Plana Simões; Rejane Maria Tommasini Grotto; Marjorie de Assis Golim; Giovanni Faria Silva
Journal:  Clin Exp Med       Date:  2021-04-09       Impact factor: 3.984

3.  HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathway.

Authors:  Qianqian Zhang; Yang Wang; Naicui Zhai; Hongxiao Song; Haijun Li; Yang Yang; Tianyang Li; Xiaolin Guo; Baorong Chi; Junqi Niu; Ian Nicholas Crispe; Lishan Su; Zhengkun Tu
Journal:  Sci Rep       Date:  2016-10-27       Impact factor: 4.379

4.  Immunomodulatory Effects of Rhinovirus and Enterovirus Infections During the First Year of Life.

Authors:  Terhi Ruohtula; Anita Kondrashova; Jussi Lehtonen; Sami Oikarinen; Anu-Maaria Hämäläinen; Onni Niemelä; Aleksandr Peet; Vallo Tillmann; Janne K Nieminen; Jorma Ilonen; Mikael Knip; Outi Vaarala; Heikki Hyöty
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.